Wobbe Hospes

Wobbe Hospes

Auto-generated profile, based on publicly available information

Wobbe Hospes


Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 June 2026 in SSRN Electronic Journal
Verified
Preprint
Open access
WHWobbe Hospes
Wobbe Hospes
IVIngeborg Vriens
Ingeborg Vriens
IBIngrid Boere
Ingrid Boere
CLChristianne Lok
Christianne Lok
BackgroundPharmacological evidence to guide anticancer drug use during pregnancy remains limited, particularly for newer targeted and immunotherapeutic agents. Given the ethical and practical barriers to conducting clinical trials, coupled with the rapid introduction of new anticancer drugs, alternative strategies are needed to prioritize research and support model-informed dosing approaches.MethodsWe conducted an international electronic survey among clinicians experienced in the management of cancer during pregnancy. Respondents reported trimester-specific prescribing or consideration of anticancer and supportive drugs across multiple tumour types and rated the perceived need for further research. Prescribing behaviour was analysed at the physician–drug level using descriptive statistics, risk differences, and exploratory mixed-effects models. Survey findings were interpreted with input from a multidisciplinary focus group.ResultsTwenty-three clinicians completed the survey. Across tumour types, non-prescription predominated, particularly in the first trimester, with cautious and selective prescribing later in pregnancy. When considered, prescribing was largely confined to established anticancer drugs whereas targeted therapies and immunotherapies were generally avoided. Despite limited current use, a substantial perceived need for further research was identified. Immune checkpoint inhibitors and selected targeted agents were prioritized. Similar uncertainty was observed for commonly used supportive therapies, despite frequent prescribing.ConclusionsClinicians report caution in prescribing anticancer drugs during pregnancy alongside a clear need for further research, particularly for immunotherapies, targeted agents, and selected supportive drugs. These findings support a focused, model-informed research strategy to address key evidence gaps where clinical trials are not feasible.